93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting Manageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone pr

Median seizure reduction of 78% through seven months of observation at the third dose level Clinically meaningful gains in multiple measures of neurodevelopment across initial three dose levels, including substantial improvements in cognitive skills by 16 weeks in participants dosed before two years of age Well-tolerated across all four dose levels, with no treatment-related serious adverse events Efficacy data from the fourth dose level and pivotal study initiation expected

Safusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-free at 24 months Findings supported recent favorable interactions with FDA where alignment was reached on modifying the ongoing G203 into a pivotal trial in high-grade gliomas NEW YORK--(BUSINESS WIRE) -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlyingAATD, with Investigational New Drug filing expected by the end of the year  Tessera to receive $150 million, inclusive of a cash upfront and equity investment fromRegeneron; companies to share worldwide development costs and future profits 50:50 Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines andclinical development with Tessera’s pioneering